Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/...

por Malik, Zafar, Di Lorenzo, Giuseppe, Pichler, Angelika, De Giorgi, Ugo, Hitier, Simon, Ecstein-Fraisse, Evelyne, Ozatilgan, Ayse, Carles, Joan
Publicado 2020

Post Hoc Health‐Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies

por Thiery‐Vuillemin, Antoine, Fizazi, Karim, Sartor, Oliver, Oudard, Stéphane, Bury, Denise, Ozatilgan, Ayse, Poole, Elizabeth M., Eisenberger, Mario, de Bono, Johann
Publicado 2021

Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD

por de Wit, Ronald, Freedland, Stephen J., Oudard, Stephane, Marinov, Georgi, Capart, Philippe, Combest, Austin J., Peterson, Ryan, Ozatilgan, Ayse, Morgans, Alicia K.
Publicado 2022

Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early acces...

por Malik, Zafar, Heidenreich, Axel, Bracarda, Sergio, Ardavanis, Alexandros, Parente, Philip, Scholz, Hans-Joerg, Ozatilgan, Ayse, Ecstein-Fraisse, Evelyne, Hitier, Simon, Di Lorenzo, Giuseppe
Publicado 2019

Neutropenia, neutrophilia, and neutrophil–lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer

por Meisel, Alexander, de Wit, Ronald, Oudard, Stephane, Sartor, Oliver, Stenner-Liewen, Frank, Shun, Zhenming, Foster, Meredith, Ozatilgan, Ayse, Eisenberger, Mario, de Bono, Johann S.
Publicado 2022

An observational, multicentre study of cabazitaxel in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel (CAPRISTANA)

por Carles, Joan, Pichler, Angelika, Korunkova, Hana, Tomova, Antoaneta, Ghosn, Marwan, El Karak, Fadi, Makdessi, Joseph, Koroleva, Irina, Barnes, Gisoo, Bury, Denise, Özatilgan, Ayse, Hitier, Simon, Katolicka, Jana
Publicado 2018

Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-...

por Suzuki, Hiroyoshi, Castellano, Daniel, de Bono, Johann, Sternberg, Cora N, Fizazi, Karim, Tombal, Bertrand, Wülfing, Christian, Foster, Meredith C, Ozatilgan, Ayse, Geffriaud-Ricouard, Christine, de Wit, Ronald
Publicado 2021

Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA

por Sumanasuriya, Semini, Seed, George, Parr, Harry, Christova, Rossitza, Pope, Lorna, Bertan, Claudia, Bianchini, Diletta, Rescigno, Pasquale, Figueiredo, Ines, Goodall, Jane, Fowler, Gemma, Flohr, Penelope, Mehra, Niven, Neeb, Antje, Rekowski, Jan, Eisenberger, Mario, Sartor, Oliver, Oudard, Stéphane, Geffriaud-Ricouard, Christine, Ozatilgan, Ayse, Chadjaa, Mustapha, Macé, Sandrine, Lord, Chris, Baxter, Joe, Pettitt, Stephen, Lambros, Maryou, Sharp, Adam, Mateo, Joaquin, Carreira, Suzanne, Yuan, Wei, de Bono, Johann S.
Publicado 2021